References
1. Selcuck A, Kilic Y, Korun O, et al. High incidence of fever in patients after biointegral pulmonic valved conduit implantation. J Card Surg. DETAILS TO BE CONFIRMED
2. Abolhoda A, Yu S, Oyarzun JR, McCormick JR, Bogden JD, Gabbay S. Calcification of bovine pericardium: Glutaraldehyde versus No-React biomodification. Ann Thorac Surg . 1996;62(1):169-174. doi:10.1016/0003-4975(96)00277-9
3. Raissadati A, Nieminen H, Haukka J, Sairanen H, Jokinen E. Late Causes of Death After Pediatric Cardiac Surgery. J Am Coll Cardiol . 2016;68(5):487-498. doi:10.1016/j.jacc.2016.05.038
4. Marianeschi SM, Iacona GM, Seddio F, et al. Shelhigh No-React porcine pulmonic valve conduit: A new alternative to the homograft. Ann Thorac Surg . 2001;71(2):619-623. doi:10.1016/S0003-4975(00)02456-5
5. Grohmann J, Höhn R, Fleck T, et al. No-React® Injectable BioPulmonicTM valves re-evaluated: Discouraging follow-up results. Interact Cardiovasc Thorac Surg . 2015;21(5):657-665. doi:10.1093/icvts/ivv214
6. Ishizaka T, Ohye RG, Goldberg CS, et al. Premature failure of small-sized Shelhigh No-React porcine pulmonic valve conduit model NR-4000. Eur J Cardio-thoracic Surg . 2003;23(5):715-718. doi:10.1016/S1010-7940(03)00080-0
7. Sahin A, Müggler O, Sromicki J, et al. Long-term follow-up after aortic root replacement with the Shelhigh® biological valved conduit: A word of caution! Eur J Cardio-thoracic Surg . 2016;50(6):1172-1178. doi:10.1093/ejcts/ezw167
8. Reineke DC, Kaya A, Heinisch PP, et al. Long-term follow-up after implantation of the Shelhigh® No-React® complete biological aortic valved conduit. Eur J Cardio-thoracic Surg . 2016;50(1):98-104. doi:10.1093/ejcts/ezv452
9. Kaya A, Heijmen RH, Kelder JC, Schepens MA, Morshuis WJ. Stentless biological valved conduit for aortic root replacement: Initial experience with the Shelhigh BioConduit model NR-2000C. J Thorac Cardiovasc Surg . 2011;141(5):1157-1162. doi:10.1016/j.jtcvs.2010.07.009
10. Tweddell JS, Pelech AN, Frommelt PC, et al. Factors affecting longer of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. Circulation . 2000;102(19). doi:10.1161/01.cir.102.suppl_3.iii-130
11. Niwaya K, Knott-Craig CJ, Lane MM, et al. Cryopreserved homograft valves in the pulmonary position: Risk analysis for intermediate-term failure. J Thorac Cardiovasc Surg . 1999;117(1):141-147. doi:10.1016/S0022-5223(99)70479-4
12. Kostyunin AE, Yuzhalin AE, Rezvova MA, Ovcharenko EA, Glushkova T V., Kutikhin AG. Degeneration of Bioprosthetic Heart Valves: Update 2020. J Am Heart Assoc . 2020;9(19):e018506. doi:10.1161/JAHA.120.018506
13. Mery CM, Guzmán-Pruneda FA, De León LE, et al. Risk factors for development of endocarditis and reintervention in patients undergoing right ventricle to pulmonary artery valved conduit placement Read at the 95th Annual Meeting of the American Association for Thoracic Surgery, Seattle, Washington, April 25-29, 2015. In: Journal of Thoracic and Cardiovascular Surgery . Vol 151. Mosby Inc.; 2016:432-441.e2. doi:10.1016/j.jtcvs.2015.10.069
14. Beckerman Z, De León LE, Zea-Vera R, Mery CM, Fraser CD. High incidence of late infective endocarditis in bovine jugular vein valved conduits. J Thorac Cardiovasc Surg . 2018;156(2):728-734.e2. doi:10.1016/j.jtcvs.2018.03.156
15. Gröning M, Tahri NB, Søndergaard L, Helvind M, Ersbøll MK, Ørbæk Andersen H. Infective endocarditis in right ventricular outflow tract conduits: A register-based comparison of homografts, Contegra grafts and Melody transcatheter valves. Eur J Cardio-thoracic Surg . 2019;56(1):87-93. doi:10.1093/ejcts/ezy478
Acknowledgement: This study was supported by the British Heart Foundation and the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol.